Abstracts tagged "Adalimumab"

Abstract Number: 1422 • 2017 ACR/ARHP Annual Meeting
Impact of Adalimumab on Prednisone Use in Patients with Rheumatoid Arthritis in a Real World Setting – Results from the Corrona Registry
Dimitrios A. Pappas¹, Chitra Karki¹, Heather J. Litman¹, Taylor Blachley¹, Jessica L. Suboticki², Jenny Griffith³ and Joel Kremer⁴, ¹Corrona, LLC, Southborough, MA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc., North Chicago, IL, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Steroids are used to reduce inflammation and pain among rheumatoid arthritis (RA) patients, but they can cause harmful side effects, and in some patients,…
Abstract Number: 2495 • 2017 ACR/ARHP Annual Meeting
Biosimilarity between Humira® and the Biosimilar Candidate SB5 in Product Quality
Nayoung Lee, Minlee Kim, JongAh Joanne Lee, Soohwan Kim and Hahymn Yang, Samsung Bioepis, Incheon, Korea, Republic of (South)
Background/Purpose: A biosimilar is a biopharmaceutical product that is highly similar to an already licensed one in terms of quality, safety, and efficacy. We (Samsung…
Abstract Number: 1424 • 2017 ACR/ARHP Annual Meeting
Impact of Glucocorticoid Therapy on the Efficacy of SC Abatacept or Adalimumab in RA Patients with Inadequate Response to MTX: A Post Hoc Analysis of Data from a Head-to-Head Trial
Yannick Degboé^1,2, Michael Schiff³, Michael Weinblatt⁴, Roy Fleischmann⁵, HA Ahmad⁶ and Arnaud Constantin^2,7, ¹Toulouse University Hospital, Toulouse, France, ²Université Paul Sabatier, Toulouse, France, ³University of Colorado, Denver, CO, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Purpan University Hospital, Toulouse, France
Background/Purpose: In patients with RA, low-dose glucocorticoids (GCs) have been shown to increase clinical, functional and radiographic efficacy when combined with conventional synthetic DMARDs;1 however,…
Abstract Number: 2799 • 2017 ACR/ARHP Annual Meeting
Efficacy, Safety and Immunogenicity in Randomized, Double-Blind (DB) and Open-Label Extension (OLE) Studies Comparing FKB327, an Adalimumab Biosimilar, with the Adalimumab Reference Product (Humira®; RP) in Patients (pts) with Active Rheumatoid Arthritis (RA)
Mark C. Genovese¹, Josephine Glover², Nobuhito Matsunaga³, Diane Chisholm⁴ and Rieke Alten⁵, ¹Stanford University Medical Center, Palo Alto, CA, ²Coephycient Pharmaceutical Consultancy, Guildford, United Kingdom, ³Fujifilm Kyowa Kirin Biologics, Chiyoda-ku, Tokyo, Japan, ⁴Fujifilm Kyowa Kirin Biologics, Galashiels, United Kingdom, ⁵University Medicine Berlin, Berlin, Germany
Background/Purpose: FKB327 is a proposed biosimilar of the adalimumab RP. A randomized, DB, Phase 3 study (NCT02260791) compared the efficacy, safety, pharmacokinetics (PK) and immunogenicity…
Abstract Number: 1471 • 2017 ACR/ARHP Annual Meeting
Flare Incidence and Predictive Factors in a Population of Patients with Rheumatoid Arthritis Under Optimised Treatment with Adalimumab and Infliximab
Amara Pieren¹, Dora Pascual-Salcedo², Pilar Aguado³, Gema Bonilla⁴, Eugenio De Miguel⁵, Irene Monjo⁶, Laura Nuño³, Diana Peiteado³, Alejandro Villalba³, Enrique Moral Coro⁴, C. Tornero⁷, Patricia Bogas⁴, Alejandro Balsa³ and Chamaida Plasencia-Rodriguez⁴, ¹Rheumatologyº, Hospital La Paz, Madrid, Spain, ²Immuno-Rheumatology Research group, La Paz University Hospital, Madrid, Spain, ³Rheumatology, La Paz University Hospital, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, ⁶Internal Medicine, Hospital Universitario La Paz, MADRID, Spain, ⁷Rheumatology, Rheumatology. La Paz University Hospital, Spain., Madrid, Spain
Background/Purpose:Anti-TNF has drastically changed the prognostic of the RA,carrying an important healthcare expense.This is why,optimisation seems a successful strategy that should not be linked to…
Abstract Number: 2868 • 2017 ACR/ARHP Annual Meeting
Pharmacodynamic Analysis of Whole Blood Gene Expression over 2 Years in a Phase IIIb Head-to-Head Trial of Abatacept and Adalimumab in Patients with RA
O Jabado¹, MA Maldonado¹, Michael Schiff², Michael Weinblatt³, Roy Fleischmann⁴, William H. Robinson⁵, A Greenfield¹ and SE Connolly¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²University of Colorado, Denver, CO, ³Brigham and Women’s Hospital, Boston, MA, ⁴Metroplex Clinical Research Center Dallas, Dallas, TX, ⁵Stanford University, Palo Alto, CA
Background/Purpose: The head-to-head AMPLE study compared the safety and efficacy of abatacept (co-stimulatory modulator) versus adalimumab (TNFα inhibitor) for treatment of RA over 2 years.…
Abstract Number: 1521 • 2017 ACR/ARHP Annual Meeting
Impact of Time Since Diagnosis, Age, and Number of Prior Non-Steroidal Anti-Inflammatory Drugs on 52-Week Clinical Response to Adalimumab in Patients with Ankylosing Spondylitis
Joachim Sieper¹, Atul A. Deodhar², Maja Hojnik³, Ying Zhang⁴ and Maxime Dougados⁵, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Oregon Health & Science University, Portland, OR, ³AbbVie, Ljubljana, Slovenia, ⁴AbbVie Inc., North Chicago, IL, ⁵René Descartes University and Hôpital Cochin, Paris, France
Background/Purpose : Ankylosing spondylitis (AS) patients (pts) were found to respond better to TNF inhibitors (TNFi) if treated early in the disease course.1 The actual…
Abstract Number: 2879 • 2017 ACR/ARHP Annual Meeting
Switching from Adalimumab to Chs-1420: A Randomized, Double-Blind Global Clinical Trial in Patients with Psoriasis and Psoriatic Arthritis
Jennifer Hodge, Hong Tang, Paula O'Connor and Barbara Finck, Coherus BioSciences, Inc., Redwood City, CA
Background/Purpose: CHS-1420 is a proposed biosimilar to adalimumab. A phase 3, randomized, double-blind, multicenter study evaluated the equivalence of CHS-1420 to adalimumab in patients with…
Abstract Number: 1522 • 2017 ACR/ARHP Annual Meeting
Patients with Ankylosing Spondylitis Had Better Adalimumab Survival Than Patients with Non-Radiographic Axial Spondyloarthritis
Alper Sari¹, Berkan Armagan¹, Abdulsamet Erden², Levent Kilic^1,2, Omer Karadag^2,3, Ali Akdogan¹, Umut Kalyoncu² and Ihsan Ertenli², ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Department of Internal Medicine, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom
Patients with ankylosing spondylitis had better adalimumab survival than patients with non-radiographic axial spondyloarthritis Background/Purpose: Drug survival rate is generally accepted as a reliable indicator of…
Abstract Number: 1906 • 2017 ACR/ARHP Annual Meeting
Tofacitinib with and without Methotrexate Versus Adalimumab with Methotrexate for the Treatment of Rheumatoid Arthritis: Patient-Reported Outcomes from a Phase 3b/4 Randomized Trial
Vibeke Strand¹, Eduardo Mysler², Robert J Moots³, Gene Wallenstein⁴, Ryan DeMasi⁵, Zhen Luo⁶, Koshika Soma⁴, Noriko Iikuni⁷ and Roy Fleischmann⁸, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Organización Médica de Investigación, Buenos Aires, Argentina, ³Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Shanghai, China, ⁷Pfizer Inc, New York, NY, ⁸Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared patient-reported outcomes (PROs) among patients receiving tofacitinib monotherapy,…
Abstract Number: 515 • 2017 ACR/ARHP Annual Meeting
Leukopenia and Tumor Necrosis Factor Alpha Inhibitor Therapy
Wenlu Xiong¹, Rochella A. Ostrowski², William Adams³ and Rodney Tehrani⁴, ¹Rheumatology, Vanderbilt University Medical Center, Nashville, TN, ²Rheumatology, Loyola University Medical Center, Maywood, IL, ³Clinical Research Office, Loyola University Medical Center, Maywood, IL, ⁴Rheumatology & Immunology, Loyola University Medical Center, Maywood, IL
- Background/Purpose: Tumor necrosis factor (TNF) alpha, a key proinflammatory cytokine in rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), has been a major target in…
Abstract Number: 2017 • 2017 ACR/ARHP Annual Meeting
Prospective Study of Bio-Free Remission Maintenance Using Ultrasonography in Rheumatoid Arthritis Patients: 52-Week Result
Koichi Amano¹, Kazutoshi Aoki², Yoshiaki Kuga³, Koji Nishimura⁴, Hayato Nagasawa⁵, Takuma Tsuzuki Wada⁶, Kenji Takagi⁷, Junji Hayashi⁸, Motohide Kaneko⁹, Ryota Sakai¹⁰, Akiko Shibata¹¹, Kentaro Chino¹¹, Shuntaro Saito¹¹, Ayumi Okuyama¹², Tsuneo Kondo¹², Hirofumi Takei¹² and Toshihide Mimura¹³, ¹Department of Rheumatology and Clinical Immunology,, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ²Aoki Clinic, Saitama, Japan, ³Wakaba Hospital, Sakado, Japan, ⁴internal medicine, Saitama Medical Center, Japan Community Health care Organization, Saitama, Japan, ⁵Nagasawa Clinic, Kawagoe, Japan, ⁶Department of Rheumatology and Applied Immunology, Faculty of Medicine,, Saitama Medical University, Saitama, Japan, ⁷Rheumatology and Clinical Immunology, Higashi-Omiya General Hospital, Saitama, Japan, ⁸Orthopedic Surgery, Niizashiki Chuo General Hospital, Niiza, Japan, ⁹Kaneko Clinic, Kawaguchi, Japan, ¹⁰Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan, ¹¹Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan, ¹²Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ¹³Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Recently, a significant number of rheumatoid arthritis (RA) patients can reach low disease activity (LDA) by using biologics such as adalimumab. However biologics therapy…
Abstract Number: 611 • 2017 ACR/ARHP Annual Meeting
Effectiveness of Early Adalimumab Therapy in Psoriatic Arthritis Patients from Reuma.Pt
Helena Santos¹, Mónica Eusébio², Joana Borges³, Diana Gonçalves⁴, Pedro Ávila-Ribeiro⁵, Daniela Santos Faria⁶, Carina Lopes⁷, João Rovisco⁸, Ana Águeda⁹, Patrícia Nero¹⁰, Paula Valente¹¹, Ana Rita Cravo¹² and Maria José Santos¹³, ¹Instituto Português de Reumatologia, Lisbon, Portugal, ²Sociedade Portuguesa de Reumatologia, LIsboa, Portugal, ³Instituto Português de Reumatologia, Lisboa, Portugal, ⁴Centro Hospitalar de São João, Coimbra, Portugal, ⁵Centro Hospitalar Lisboa Norte, Lisbon, Portugal, ⁶ULSAM, Ponte de Lima, Portugal, ⁷Hospital de Egas Moniz-CHLO, Lisbon, Portugal, ⁸Centro Hospitalar e Universitário de Coimbra, Lisbon, Portugal, ⁹Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ¹⁰Hospital CUF Descobertas, Lisbon, Portugal, ¹¹Centro Hospitalar Entre o Douro e Vouga, Lisbon, Portugal, ¹²Medical, AbbVie, Lisbon, Portugal, ¹³Reuma.pt, Almada, Portugal, Almada, Portugal
Background/Purpose: There is a lack of evidence on the effect of biologics in early treatment of psoriatic arthritis (PsA) patients (Pts). Benefit of concomitant use…
Abstract Number: 2271 • 2017 ACR/ARHP Annual Meeting
Safety of Adalimumab±Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Hermine I. Brunner¹, Nicola Ruperto², Kabita Nanda³, Mary Toth⁴, Ivan Foeldvari⁵, John F. Bohnsack⁶, Diana Milojevic⁷, C. Egla Rabinovich⁸, Daniel J Kingsbury⁹, Katherine Marzan¹⁰, Pierre Quartier¹¹, Kirsten Minden¹², Elizabeth Chalom¹, Gerd Horneff¹³, Rolf M. Kuester¹⁴, Jason A Dare¹⁵, Mareike Bereswill¹⁶, Jasmina Kalabic¹⁶, Hartmut Kupper¹⁶, Daniel J Lovell¹ and Alberto Martini², ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²PRINTO-IRCCS Gaslini, Genova, Italy, ³University of Washington School of Medicine and Seattle Children's Hospital, Bayside, NY, ⁴Akron Children's Hospital, Akron, OH, ⁵Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ⁶University of Utah, Department of Pediatrics, Salt Lake City, UT, ⁷The Floating Hospital for Children at Tufts Medical Center, Boston, MA, ⁸Duke University Medical Center, Durham, NJ, ⁹Randall Children’s Hospital at Legacy Emanuel, Portland, OR, ¹⁰Children's Hospital Los Angeles, Los Angeles, CA, ¹¹Hopital Necker-Enfants Malades, Paris, France, ¹²Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ¹³Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁴Orthopädiezentrum Altona, Hamburg, Germany, ¹⁵Arkansas Children’s Hospital, Little Rock, AR, ¹⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: JIA is the most common chronic inflammatory rheumatic disease of childhood. Due to their known safety and efficacy, TNF inhibitors are used for long-term…
Abstract Number: 619 • 2017 ACR/ARHP Annual Meeting
Integrated Efficacy Analysis of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis
Peter Nash¹, Laura C Coates², Roy Fleischmann³, Kim Papp⁴, Juan J. Gomez-Reino⁵, Keith S Kanik⁶, Cunshan Wang⁶, Joseph Wu⁶, Thijs Hendrikx⁷ and William C Ports⁶, ¹Department of Medicine, University of Queensland, St Lucia, Brisbane, Australia, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁴Probity Medical Research and K. Papp Clinical Research Inc, Waterloo, ON, Canada, ⁵Fundacion Ramon Dominguez, Hospital Clinico Universitario, Santiago de Compostela, Spain, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of psoriatic arthritis (PsA). We examined tofacitinib efficacy in patients (pts) with active…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].